-

PerkinElmer Launches Solus Listeria monocytogenes ELISA Assay for Testing Across Food and Environmental Samples

Solution Receives AOAC® PTM SM Certification

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched the PerkinElmer Solus Listeria monocytogenes ELISA Assay. This new offering will help high throughput food processors and contract labs focus on L. mono testing for food and environmental surface samples. In sync with leading industry standards, the new solution is being introduced with Performance Tested Method SM (PTM) certification from AOAC® INTERNATIONAL (Association of Official Analytical Collaboration).

Though Listeria makes fewer people sick than other foodborne pathogens, the presence of the bacteria is more pervasive and Listeriosis carries a 20 – 30%* mortality rate if contracted by pregnant women, those over 65, or people with compromised immune systems (*Source: https://www.who.int/ith/diseases/listeriosis/en/.)

The PerkinElmer Solus L. mono assay detects this harmful bacteria with accuracy, specificity and convenience, especially for geographic regions whose regulations require separate reporting for L. mono.

Simplifying workflows, the new assay features the ability to employ a single protocol for both food samples (such as unpasteurized cheeses, meats, shrimp and vegetables) as well as environmental sample swabs and sponges. A simple 24 hour + 24 hour enrichment process leverages supplemented standard media and incubation parameters are shared across matrices. Users can choose to process samples manually or automate them with Dynex Technologies’ DS-2® system.

“Listeria is a concern for food processors and consumers because it can live anywhere and can create lethal illness,” said Greg Sears, Vice President and General Manager, Food, PerkinElmer. “Our new Solus L. mono assay with AOAC PTM certification helps labs and processors be even more vigilant and precise in detecting and fighting back against this challenge to the global food chain.”

The new Solus L. mono assay, joins PerkinElmer’s foodborne pathogen portfolio including the wider spectrum Solus One Listeria assay, Solus One Salmonella, and Solus E. coli O157 ELISA. These innovations are part of the company’s broader food safety and quality solutions for grain, dairy, meats, produce, edible oils, seafood, and cannabis. For more information please visit www.perkinelmer.com/category/food-safety-quality.

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Contacts

Jennifer McNeil
+1 508 361-5901
Jennifer.mcneil@perkinelmer.com

PerkinElmer, Inc.

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Summary
The new PerkinElmer Solus Listeria monocytogenes ELISA Assay focuses on L. mono testing for food and environmental surface safety.
Release Versions

Contacts

Jennifer McNeil
+1 508 361-5901
Jennifer.mcneil@perkinelmer.com

More News From PerkinElmer, Inc.

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for t...

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from disco...

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Inves...
Back to Newsroom